BACKGROUND: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment resistance to the first-line R-CHOP regimen. ATP binding cassette (ABC) transporters and survivin might play a role in multidrug resistance (MDR) in various tumors. The aim was to investigate if the coexpression of ABC transporters and survivin was associated with R-CHOP treatment response. METHODS: The expression of Bcl-2, survivin, P-glycoprotein/ABCB1, MRP1/ABCC1, and BCRP/ABCC2 was analyzed using immunohistochemistry in tumor specimens obtained from patients with DLBCL, and classified according to the treatment response as Remission, Relapsed, and (primary) Refractory groups. All patients received R-CHOP or equivalent treatment. RESULTS: Bcl-2 was in strong positive correlation with clinical parameters and all biomarkers except P-gp/ABCB1. The overexpression of MRP1/ABCC1, survivin, and BCRP/ABCC2 presented as high immunoreactive scores (IRSs) was detected in the Refractory and Relapsed groups (p < 0.05 vs. Remission), respectively, whereas the IRS of P-gp/ABCB1 was low. Significant correlations were found among either MRP1/ABCC1 and survivin or BCRP/ABCC2 in the Refractory and Relapsed groups, respectively. In multiple linear regression analysis, ECOG status along with MRP1/ABCC1 or survivin and BRCP/ABCG2 was significantly associated with the prediction of the R-CHOP treatment response. CONCLUSIONS: DLBCL might harbor certain molecular signatures such as MRP1/ABCC1, survivin, and BCRP/ABCC2 overexpression that can predict resistance to R-CHOP.

Center for Biomedical Research Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Clinic of Hematology University Clinical Center of Serbia 2 Pasterova 11000 Belgrade Serbia

Department for Experimental Toxicology and Pharmacology National Poison Control Centre Military Medical Academy Crnotravska 17 11000 Belgrade Serbia

Department of Analytical Chemistry Faculty of Chemistry University of Belgrade Studenski trg 16 11000 Belgrade Serbia

Department of Chemistry Faculty of Science University of Hradec Kralove Rokitanskeho 62 50003 Hradec Kralove Czech Republic

Department of Gynecology and Obstetrics Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Hematology Clinic of Internal Medicine University Clinical Center Republic of Srpska 12 Beba 78000 Banja Luka Bosnia and Herzegovina

Department of Hematology Faculty of Medicine University of Belgrade 11000 Belgrade Serbia

Department of Internal Medicine Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Pathology Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Pharmacology Toxicology and Clinical Pharmacology Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Surgery Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Institute for Medical Research National Institute of the Republic of Serbia Department for Cardiovascular Research University of Belgrade Dr Subotića 4 11000 Belgrade Serbia

Medical Faculty of the Military Medical Academy University of Defence Crnotravska 17 11000 Belgrade Serbia

Special Police Unit Ministry of Interior Trebevićka 12 A 11030 Belgrade Serbia

Zobrazit více v PubMed

He M.Y., Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021;35:2151–2165. doi: 10.1038/s41375-021-01285-3. PubMed DOI

Thandra K.C., Barsouk A., Saginala K., Padala S.A., Barsouk A., Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. Med. Sci. 2021;9:5. doi: 10.3390/medsci9010005. PubMed DOI PMC

Schmitz R., Wright G.W., Huang D.W., Johnson C.A., Phelan J.D., Wang J.Q., Roulland S., Kasbekar M., Young R.M., Shaffer A.L., et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2018;378:1396–1407. doi: 10.1056/NEJMoa1801445. PubMed DOI PMC

Choueiry F., Singh S., Sircar A., Laliotis G., Sun X., Chavdoula E., Zhang S., Helmig-Mason J., Hart A., Epperla N., et al. Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. Cancers. 2021;13:2146. doi: 10.3390/cancers13092146. PubMed DOI PMC

Salles G., Barrett M., Foà R., Maurer J., O’Brien S., Valente N., Wenger M., Maloney D.G. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv. Ther. 2017;34:2232–2273. doi: 10.1007/s12325-017-0612-x. PubMed DOI PMC

Pfreundschuh M., Kuhnt E., Trümper L., Osterborg A., Trneny M., Shepherd L., Gill D.S., Walewski J., Pettengell R., Jaeger U., et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-Bcell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022. doi: 10.1016/S1470-2045(11)70235-2. PubMed DOI

Lenz G. Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications. Cancers. 2015;7:811–822. doi: 10.3390/cancers7020812. PubMed DOI PMC

Wang L., Li L.R. R-CHOP resistance in diffuse large B-cell lymphoma: Biological and molecular mechanisms. Chin. Med. J. 2020;134:253–260. doi: 10.1097/CM9.0000000000001294. PubMed DOI PMC

Rovira J., Valera A., Colomo L., Setoain X., Rodríguez S., Martínez-Trillos A., Giné E., Dlouhy I., Magnano L., Gaya A., et al. Prognosis of Patients with Diffuse Large B Cell Lymphoma Not Reaching Complete Response or Relapsing after Frontline Chemotherapy or Immunochemotherapy. Ann. Hematol. 2015;94:803–812. doi: 10.1007/s00277-014-2271-1. PubMed DOI PMC

Crump M., Neelapu S.S., Farooq U., Van Den Neste E., Kuruvilla J., Westin J., Link B.K., Hay A., Cerhan J.R., Zhu L., et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study. Blood. 2017;130:1800–1808. doi: 10.1182/blood-2017-03-769620. PubMed DOI PMC

Berendsen M.R., Stevens W.B.C., van den Brand M., van Krieken J.H., Scheijen B. Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers. 2020;12:3553. doi: 10.3390/cancers12123553. PubMed DOI PMC

Pi M., Kuang H., Yue C., Yang Q., Wu A., Li Y., Assaraf Y.G., Yang D.H., Wu S. Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resist. Updat. 2022;61:100822. doi: 10.1016/j.drup.2022.100822. PubMed DOI

Zhang J., Gu Y., Chen B. Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL. Cancer Manag. Res. 2023;15:245–255. doi: 10.2147/CMAR.S400013. PubMed DOI PMC

Kathawala R.J., Gupta P., Ashby C.R., Chen Z.-S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist. Updat. 2015;18:1–17. doi: 10.1016/j.drup.2014.11.002. PubMed DOI

Singh R.R., Kunkalla K., Qu C., Schlette E., Neelapu S.S., Samaniego F., Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011;30:4874–4886. doi: 10.1038/onc.2011.195. PubMed DOI PMC

Ohsawa M., Ikura Y., Fukushima H., Shirai N., Sugama Y., Suekane T., Hirayama M., Hino M., Ueda M. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology. 2005;68:422–431. doi: 10.1159/000086984. PubMed DOI

Greaves W., Xiao L., Sanchez-Espiridion B., Kunkalla K., Dave K.S., Liang C.S., Singh R.R., Younes A., Medeiros L.J., Vega F. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J. Hematol. Oncol. 2012;5:7. doi: 10.1186/1756-8722-5-47. PubMed DOI PMC

Wang J.-Q., Li J.Y., Teng Q.-X., Lei Z.-N., Ji N., Cui Q., Zeng L., Pan Y., Yang D.-H., Chen Z.-S. Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells. Cancers. 2020;12:466. doi: 10.3390/cancers12020466. PubMed DOI PMC

Liu K., Song J., Yan Y., Zou K., Che Y., Wang B., Li Z., Yu W., Guo W., Zou L., et al. Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway. Transl. Oncol. 2021;14:100876. doi: 10.1016/j.tranon.2020.100876. PubMed DOI PMC

Liu M., Gao H., He Y., Sun X., Zhang L. Upregulation of miR-101-3p Overcomes Ibrutinib Resistance by Targeting ABCC5 in Diffuse Large B-Cell Lymphoma (DLBCL) J. Hard. Tissue. Biol. 2023;32:11–20. doi: 10.2485/jhtb.32.11. DOI

Tsang T.J., Hsueh Y.C., Wei E.I., Lundy D.J., Cheng B., Chen Y.T., Wang S.S., Hsieh P.C.H. Subcellular localization of survivin determines its function in cardiomyocytes. Theranostics. 2017;7:4577–4590. doi: 10.7150/thno.20005. PubMed DOI PMC

Sah N.K., Seniya C. Survivin splice variants and their diagnostic significance. Tumor Biol. 2015;36:6623–6631. doi: 10.1007/s13277-015-3865-5. PubMed DOI

Bernardo P.S., Lemos L.G.T., de Moraes G.N., Maia R.C. Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications. Blood Rev. 2020;43:100671. doi: 10.1016/j.blre.2020.100671. PubMed DOI

Zhang Y., Wang J., Sui X., Li Y., Lu K., Fang X., Jiang Y., Wang X. Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis. Medicine. 2015;94:e1432. doi: 10.1097/MD.0000000000001432. PubMed DOI PMC

Mitrović Z., Ilić I., Aurer I., Kinda S.B., Radman I., Dotlić S., Ajdukovic R., Labar B. Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP. Pathol. Oncol. Res. 2011;17:243–247. doi: 10.1007/s12253-010-9304-4. PubMed DOI

Liu Z., Xu-Monette Z.Y., Cao X., Manyam G.C., Wang X., Tzankov A., Xia Y., Li X., Visco C., Sun R., et al. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod. Pathol. 2015;28:1297–1314. doi: 10.1038/modpathol.2015.94. PubMed DOI

Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. PubMed DOI PMC

Lister T.A., Crowther D., Sutcliffe S.B., Glatstein E., Canellos G.P., Young R.C., Rosenberg S., Coltman C.A., Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol. 1989;7:1630–1636. doi: 10.1200/JCO.1989.7.11.1630. PubMed DOI

Schwartz L.H., Litière S., de Vries E., Ford R., Gwyther S., Mandrekar S., Shankar L., Bogaerts J., Chen A., Dancey J., et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur. J. Cancer. 2016;62:132–137. doi: 10.1016/j.ejca.2016.03.081. PubMed DOI PMC

Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-López A., Hagenbeek A., et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999;17:1244. doi: 10.1200/JCO.1999.17.4.1244. PubMed DOI

Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Müller-Hermelink H., Campo E., Braziel R.M., Jaffe E.S., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282. doi: 10.1182/blood-2003-05-1545. PubMed DOI

International Non-Hodgkin’s Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1993;329:987–994. doi: 10.1056/NEJM199309303291402. PubMed DOI

Nežić L., Škrbić R., Amidžić L., Gajanin R., Kuča K., Jaćević V. Simvastatin Protects Cardiomyocytes Against Endotoxin-induced Apoptosis and Up-regulates Survivin/NF-kB/p65 Expression. Sci. Rep. 2018;8:14652. doi: 10.1038/s41598-018-32376-4. PubMed DOI PMC

Nežić L., Amidžić L., Škrbić R., Gajanin R., Nepovimova E., Vališ M., Kuča K., Jaćević V. Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-kB/p65 Expression. Front. Pharmacol. 2019;10:54. doi: 10.3389/fphar.2019.00054. PubMed DOI PMC

Szczuraszek K., Materna V., Halon A., Mazur G., Wróbel T., Kuliczkowski K., Maciejczyk A., Zabel M., Drag M., Dietel M., et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin’s lymphomas. Oncol. Rep. 2009;22:1315–1323. doi: 10.3892/or_00000570. PubMed DOI

Tsuyama N., Sakata S., Baba S., Mishima Y., Nishimura N., Ueda K., Yokoyama M., Terui Y., Hatake K., Kitagawa M., et al. BCL2 expression in DLBCL: Reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130:489–500. doi: 10.1182/blood-2016-12-759621. PubMed DOI

Li L., Li Y., Que X., Gao X., Gao Q., Yu M., Ma K., Xi Y., Wang T. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis. Sci. Rep. 2018;8:6267. doi: 10.1038/s41598-018-24631-5. PubMed DOI PMC

Krull J.E., Wenzl K., Hartert K.T., Manske M.K., Sarangi V., Maurer M.J., Larson M.C., Nowakowski G.S., Ansell S.M., McPhail E., et al. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer J. 2020;10:117. doi: 10.1038/s41408-020-00382-3. PubMed DOI PMC

Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.O., Berti E., Bhagat G., Borges A.M., Boyer D., Calaminici M., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–1748. doi: 10.1038/s41375-022-01620-2. PubMed DOI PMC

Li L., Zhang X., Zhang T., Song Z., Hu G., Li W., Li L., Qiu L., Qian Z., Zhou S., et al. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. Clin. Lymphoma Myeloma Leuk. 2018;18:e381–e389. doi: 10.1016/j.clml.2018.06.010. PubMed DOI

Barraclough A., Alzahrani M., Ettrup M.S., Bishton M., van Vliet C., Farinha P., Gould C., Birch S., Sehn L.H., Sovani V., et al. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: A retrospective multicenter study. Blood Adv. 2019;3:2013–2021. doi: 10.1182/bloodadvances.2019000251. PubMed DOI PMC

Camicia R., Winkler H.C., Hassa P.O. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: A comprehensive review. Mol. Cancer. 2015;14:207. doi: 10.1186/s12943-015-0474-2. PubMed DOI PMC

Andreadis C., Gimotty P.A., Wahl P., Hammond R., Houldsworth J., Schuster S.J., Rebbeck T.R. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007;109:3409–3416. doi: 10.1182/blood-2006-09-047621. PubMed DOI PMC

Rujirojindakul P., Aiempanakit K., Kayasut K., Lekhakula A., Sriplung H. No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma. ISRN Oncol. 2011;2011:670358. doi: 10.5402/2011/670358. PubMed DOI PMC

Tabata M., Tsubaki M., Takeda T., Tateishi K., Tsurushima K., Imano M., Satou T., Ishizaka T., Nishida S. Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells. BMC Complement. Med. Ther. 2020;20:84. doi: 10.1186/s12906-020-2879-8. PubMed DOI PMC

Steidl C., Telenius A., Shah S.P., Farinha P., Barclay L., Boyle M., Connors J.M., Horsman D.E., Gascoyne R.D. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010;116:418–427. doi: 10.1182/blood-2009-12-257345. PubMed DOI

Gündüz E., Dinçer M., Yıldız G., Bal C., Gülbaş Z. The frequency and clinical relevance of multidrug resistance protein expression in patients with lymphoma. Turk. J. Haematol. 2012;29:120–129. doi: 10.5505/tjh.2012.60362. PubMed DOI PMC

Markovic O., Marisavljevic D., Cemerikic-Martinovic V., Martinovic T., Filipovic B., Stanisavljevic D., Zivković R., Hajder J., Stanisavljevic N., Mihaljevic B. Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL) Med. Oncol. 2012;29:3515–3521. doi: 10.1007/s12032-012-0232-x. PubMed DOI PMC

Liu R., Chen Y., Liu G., Li C., Song Y., Cao Z., Li W., Hu J., Lu C., Liu Y. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797. doi: 10.1038/s41419-020-02998-6. PubMed DOI PMC